Cell Source Overview
Latest ROE for Cell Source: 25.38% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow25.38%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for CLCS is 25.38%. That is above the Healthcare sector average of -75.59%. Investors often review this figure alongside Cell Source's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, CLCS currently prints 25.38% for ROE, while the sector average sits near -75.59%. That is roughly 133.6% above the sector mean. Large gaps often invite a closer look at Cell Source's growth, margins, and balance sheet.
Return on Equity shows how effectively Cell Source converts resources into returns. At 25.38%, CLCS may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting CLCS's ROE (25.38%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Cell Source's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
